Rationale: Patients with malignant pleural effusion experience breathlessness, which is treated by drainage and pleurodesis. Incomplete drainage results in residual dyspnea and pleurodesis failure. Intrapleural fibrinolytics lyse septations within pleural fluid, improving drainage.
Objectives: To assess the effects of intrapleural urokinase on dyspnea and pleurodesis success in patients with nondraining malignant effusion.
Methods: We conducted a prospective, double-blind, randomized trial. Patients with nondraining effusion were randomly allocated in a 1:1 ratio to intrapleural urokinase (100,000 IU, three doses, 12-hourly) or matched placebo.
Measurements and Main Results: Co-primary outcome measures were dyspnea (average daily 100-mm visual analog scale scores over 28 d) and time to pleurodesis failure to 12 months. Secondary outcomes were survival, hospital length of stay, and radiographic change. A total of 71 subjects were randomized (36 received urokinase, 35 placebo) from 12 U.K. centers. The baseline characteristics were similar between the groups. There was no difference in mean dyspnea between groups (mean difference, 3.8 mm; 95% confidence interval [CI] , 212 to 4.4 mm; P = 0.36). Pleurodesis failure rates were similar (urokinase, 13 of 35 [37%]; placebo, 11 of 34 [32%]; adjusted hazard ratio, 1.2; P = 0.65). Urokinase was associated with decreased effusion size visualized by chest radiography (adjusted relative improvement, 219%; 95% CI, 228 to 211%; P , 0.001), reduced hospital stay (1.6 d; 95% CI, 1.0 to 2.6; P = 0.049), and improved survival (69 vs. 48 d; P = 0.026).
Conclusions: Use of intrapleural urokinase does not reduce dyspnea or improve pleurodesis success compared with placebo and cannot be recommended as an adjunct to pleurodesis. Other palliative treatments should be used. Improvements in hospital stay, radiographic appearance, and survival associated with urokinase require further evaluation.
Malignant pleural effusion (MPE) is common, affecting an estimated 200,000 patients per year in the United Kingdom and the United States (1, 2) , and it causes disabling dyspnea (3) . Standard treatment involves drainage via chest tube, followed by artificial synthesis of the pleural membranes (pleurodesis) to prevent recurrence (3) . However, initial drainage may be incomplete, resulting in persistent breathlessness and preventing effective pleurodesis. This is due to fibrinous adhesions within the pleural space, dividing the fluid into septations (4) . Ultrasound images demonstrate that intrapleural fibrinolytics lyse adhesions and improve drainage in MPE (5) .
Although fibrinolytics alone are of no value in pleural infection (6, 7), two small trials of intrapleural fibrinolytics for MPE suggest some benefit (8, 9) . Okur and colleagues randomized 47 patients to either streptokinase or no treatment and demonstrated a significant increase in pleural fluid drainage and lung reexpansion, but no difference in recurrence rate, after pleurodesis (9). Saydam and colleagues conducted a randomized trial of streptokinase or saline in 40 patients with loculated MPE visualized by computed tomography (8) , demonstrating significantly increased drainage, a decrease in requirement for supplementary oxygen therapy, and a nonsignificant decrease in pleural fluid recurrence in the first month after streptokinase. However, no trial to date has assessed the utility of intrapleural fibrinolysis on clinically meaningful outcomes in this population.
The present trial was conducted to assess the effect of adjunctive intrapleural urokinase on improving pleurodesis, addressing the key clinical outcomes of dyspnea and pleurodesis success in patients with nondraining MPE. Some of the results of this study were previously reported in the form of an abstract (10).
Methods

Study Design
The TIME3 trial (Third Therapeutic Intervention in Malignant Effusion Trial) was a double-blind, placebocontrolled, randomized trial in which investigators recruited subjects from 12 British hospitals. Ethical 
Participants
Adult participants with a diagnosis of MPE with a patent, correctly sited chest tube inserted for dyspnea relief and significant residual pleural fluid gave written informed consent before enrollment. The diagnosis was established by either histocytological proof of pleural malignancy or a recurrent, large pleural effusion in the context of histologically proven cancer outside the pleural space. To be included, patients initially had to have greater than 25% opacification of the hemithorax by residual fluid seen on a chest radiograph, but this was altered in March 2011 to either greater than 15% opacification of the hemithorax on a chest radiograph or greater than 2 cm of loculated pleural fluid visible on an ultrasound. This trial modification was made in response to increasing use of thoracic ultrasound in clinical practice in the United Kingdom and to improve study recruitment.
Exclusion criteria were age less than 18 years, expected survival less than 28 days, known underlying trapped lung of sufficient severity that pleurodesis would be futile, previous lobectomy or pneumonectomy on the side of the effusion, pleural infection, previous intrapleural fibrinolytic use, known urokinase allergy, coincidental stroke, major hemorrhage or major trauma, major surgery in the previous 5 days, chylothorax, pregnancy, lactating mothers, irreversible bleeding diathesis or platelet count less than 100 3 10 9 , irreversible visual impairment, and inability to consent to participate or comply with the protocol. Initially, patients with highly chemotherapy-responsive tumors, such as small cell lung cancer, were excluded unless the patient had already undergone chemotherapy, but this exclusion criterion was removed in March 2011.
Randomization and Masking
Patients were randomized in a 1:1 ratio to urokinase or matched identical placebo using minimization, with a random component of 80%, with a telephone randomization service provided by the Supported by the National Cancer Research Institute. The National Cancer Research Institute had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. 
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Unit, London. Code break was available only to the trial statistician, and this was not required at any time during the trial. Minimization criteria were histological tissue type (mesothelioma vs. nonmesothelioma), previous pleurodesis (yes or no), World Health Organization performance status (0-2 or 3/4), and recruiting center (11) . Treating physicians, patients, and outcome assessors were blinded to treatment allocation throughout the study.
Baseline Assessments (Day 0)
At baseline, patients completed a 100-mm visual analog scale (VAS) score assessing dyspnea over the preceding 24 hours. The VAS has previously been validated for assessment of dyspnea in pleural disease (12) and consists of a 100-mm line anchored with "no breathlessness" at 0 mm and "maximum possible breathlessness" at 100 mm (13) . Patients were asked to mark the line at a point representing their level of dyspnea. Patients completed the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-30) (14) , and baseline demographic and treatment data were recorded.
Trial Interventions
Three doses of urokinase (100,000 U) or exactly matched placebo vials were reconstituted in 20 ml of 0.9% saline and injected intrapleurally at 12-hourly intervals via the chest tube (Days 0-1). Twenty-four hours after the last dose (Day 2), a chest radiograph was obtained, and talc slurry pleurodesis was performed with 4 g of sterile, high-grade talc (Novatech) according to trial-specific procedures based on the national British Thoracic Society treatment guidelines (3) . Pleurodesis was performed regardless of ongoing fluid drainage volume and chest radiographic appearance. The chest tube was removed once significant drainage (.150 ml in each 24-h period) had ceased. All participants received treatment of the causative primary tumor in accordance with current guidelines and oncological advice.
Trial Assessments
Patients were followed for 12 months after randomization or until death. Patients completed VAS assessments at the same time each day for 28 days and at the 3-, 6-, and 12-month assessment points.
Data on pleurodesis failure, the EORTC QLQ-30 questionnaire, assessment of complications, and health care service use were measured at 28 days and 3, 6, and 12 months. All adverse events occurring within the first 3 days after randomization were recorded.
Trial Outcomes
Primary outcomes. The following were the two co-primary outcome measures:
1. Mean daily dyspnea over the first 28 days after enrollment measured by VAS; all patient-completed VAS scores were measured by two independent researchers, and the mean measurement was used 2. Time to pleurodesis failure, defined as symptomatic ipsilateral pleural fluid recurrence; this required one of the following to ensure clinical applicability of the study result: a. A further ipsilateral drainage procedure to control breathlessness b. Symptomatic pleural fluid recurrence as determined by the physician caring for the patient in cases where a further procedure was not conducted (for reasons including patient choice, futility or other medical reason such as anticoagulation or poor performance status) Secondary outcomes. The following were predetermined secondary outcomes:
1. Radiographic change in the area of the pleural effusion (measured as the difference in the proportion of the ipsilateral hemithorax occupied by the pleural effusion opacity on chest radiograph) on Day 2 after randomization; the chest radiograph pleural opacity was measured using a validated digital system as reported previously (6) 2. Total volume of pleural fluid drained after randomization 3. All-cause mortality to 12 months 4. Length of hospital stay after randomization 5. Frequency of serious and nonserious adverse events 6. Blood parameters, including biochemical and full blood count analysis
Statistical Methods
Data were analyzed on an intention-to-treat basis, and all randomized patients for whom an outcome was available were included in the analysis. Analyses were predetermined before data analysis, and a full statistical analysis plan was approved before assessment of any data. (Full details are available in the online supplement.) Analyses were adjusted for minimization criteria (performance status, mesothelioma, and previous pleurodesis) (15) . Stata version 12.1 software was used (2011; StataCorp). The difference between treatment groups in mean daily dyspnea VAS score over 28 days was calculated using a mixed-effects linear regression model to account for days with missing VAS scores (as an unbiased analysis that does not differentiate between scores missing due to patient death and those missing because the patient did not complete a VAS assessment on that day). Study day was modeled as a continuous variable using fractional polynomials and was included in the model as a random effect. The model adjusted for the baseline VAS score (16) to increase statistical precision.
Time to pleurodesis failure was analyzed using a competing risk model with death as the competing risk. Mean change in area of pleural effusion on Day 2 (after receipt of trial drug but before pleurodesis) was calculated using a linear regression model, adjusting for baseline proportion.
Sample Size Calculation
For the pleurodesis outcome, a 32% pleurodesis failure rate in the urokinase group and an 80% failure rate in the placebo group were assumed. With 25% loss to follow-up (resulting from expected mortality known in MPE), 68 patients were required with 90% power at a 5% significance level.
For the dyspnea outcome, power calculations based on pilot data from patients with MPE indicated 126 patients were needed to detect a 7-mm difference in VAS score for breathlessness (SD, 11 mm; 90% power; a = 0.05; 25% loss to follow-up), and therefore a recruitment target of 126 patients was chosen. Toward the end of recruitment, published data demonstrated that the minimally important difference of the VAS score for dyspnea in patients with pleural effusion was 19 mm (95% confidence interval [CI], 14-24 mm) (12) , and using these new data, the sample size required to detect a clinically important difference in dyspnea would have been 40 patients.
Results
A Consolidated Standards of Reporting Trials (CONSORT) flowchart depicting this trial is presented in Figure 1 . Seventy-one patients were recruited from 12 U.K. hospitals between September 1, 2009, and June 30, 2014, with recruitment ending because of expiry of the placebo medication. Thirty-six patients were randomized to urokinase and 35 to placebo, with the treatment groups well matched at baseline (Table 1) .
Change in VAS Dyspnea Scores
In both groups, the baseline VAS score was 38 mm (SD, 28 mm in the urokinase group and 25 mm in the placebo group) ( Table 1) . Mean VAS scores for dyspnea over 28 days were 39 mm in the urokinase group and 35 mm in the placebo group, equating to average mean differences in VAS score over 28 days from baseline of 1.4 mm (SD, 20 mm) in the urokinase group and 23.2 mm (SD, 21 mm) in the placebo group. There was no significant difference between the two groups (adjusted mean difference from baseline between groups, 23.8 mm; 95% CI, 212 to 4.4 mm; P = 0.36) (Figure 2 ). Outcome data were missing for eight patients (three in the urokinase group, five in the placebo group) for the following reasons: baseline VAS score only (n = 1) and VAS booklets not returned (n = 7). A total of 34 patients died during the first 28 days after randomization (19 in the urokinase group, 15 in the placebo group). There was no difference in the number of patients achieving a clinically significant decrease in VAS dyspnea (>19 mm) between the two groups (13 patients in the urokinase group, 15 patients in the placebo group; P = 0.09).
Pleurodesis Success
There was no significant difference in time to pleurodesis failure, which occurred in 13 of 35 (37%) of patients receiving urokinase compared with 11 of 34 (32%) receiving placebo (adjusted hazard ratio, 1.2; P = 0.65) (Figure 3) . Two patients were excluded from analysis owing to death occurring within 3 days of randomization (one in each treatment group).
All-Cause Mortality up to 12 Months
Death occurred by 12 months of follow-up in 31 of 36 patients in the urokinase group and in all patients in the placebo group. Median time to death after randomization was significantly longer in the urokinase group, with median survival of 69 (interquartile range, 24-123) days in the urokinase group and 48 (interquartile range, 31-80) days in the placebo group (adjusted analysis for minimization factors; P = 0.026) (Figure 4 ).
Radiographic Changes
Chest radiographs at baseline and Day 2 were available for 47 patients (26 in the urokinase group, 21 in the placebo group). In the urokinase group, size of effusion decreased, but in the placebo group, there was no significant change (urokinase group, 35% hemithorax opacification [SD, 20] 6.5] in the placebo group; adjusted hazard ratio, 1.6 d; 95% CI, 1.0 to 2.6; P = 0.049).
Fluid Output
Data were available for 24 of 36 patients in the urokinase group and 19 of 35 patients in the placebo group. There was no significant difference in total pleural fluid drainage between the groups from randomization to tube withdrawal, with mean drainage volume of 358 ml in the urokinase group (SD, 644) and 257 ml in the placebo group (SD, 402; adjusted mean ORIGINAL ARTICLE difference, 169 ml; 95% CI, 2111 to 448 ml; P = 0.24).
Change in Blood Parameters from Baseline to Day 3
There was no difference in change in hemoglobin, prothrombin time, or activated partial thromboplastin time between the two groups from baseline to Day 3 (see Table E1 in the online supplement). Platelet counts were higher in those treated with urokinase than in those receiving placebo (adjusted difference, 39; 95% CI, 1.6 to 76; P = 0.041).
Quality of Life
There was no difference in self-reported health status or overall quality of life between the groups at any time point (adjusted difference in health status, 1.6%; 95% CI 28.6 to 12; P = 0.76; adjusted difference in quality of life, 7.4%; 95% CI, 23.2 to 18; P = 0.18).
Adverse Events
Six serious adverse events occurred. Two deaths occurred within Days 0-3 owing to progression of underlying malignancy (one in the urokinase group, one in the placebo group), two pleural infections (one in the urokinase group, one in the placebo group), one chest tube wound dehiscence (placebo group), and one post-pleurodesis chest pain delaying discharge (urokinase group). No intrapleural hemorrhage occurred, and one patient (receiving placebo) experienced systemic (pelvic) bleeding.
Discussion
This randomized, placebo-controlled trial is the first, to our knowledge, to involve a comparison of urokinase with placebo for treatment of septated MPE, as well as the first intrapleural fibrinolytic trial to assess clinically meaningful outcomes (dyspnea and pleurodesis). Our results demonstrate no improvement in dyspnea or pleurodesis success after intrapleural urokinase despite chest radiographic evidence of significant reduction in size of pleural effusion. Study participants in our selected population had high mortality, demonstrating that the septated MPE population is likely to represent advanced malignancy. This poor survival means that interventions requiring hospital admission, such as talc pleurodesis, should be considered carefully in this population.
We observed a small but statistically significant decrease in mortality in the urokinase group, although it should be noted that fibrinolytics are not recognized to have antitumor effects, mortality was a secondary outcome, and there was an excess of patients with lung cancer in the placebo group. This study was conceived before the development of the LENT score for prognostication in patients with MPEs, so data were not collected to enable us to compare baseline prognosis between the groups (17) . Mortality outcomes were not reported in either of the previous randomized studies of intrapleural fibrinolytics in MPE (8, 9); however, this potential effect should be a subject of further studies.
Urokinase was associated with a decrease in hospital length of stay compared with placebo, despite having no effect on dyspnea or fluid output, and in the presence of improved chest radiographic appearance in the urokinase group. The reasons for shortened hospital stay using urokinase are not clear and require further investigation.
Our results support the findings of Okur and colleagues and Saydam and coworkers in the key finding that lung reexpansion is improved, but no change in pleurodesis success is observed, after administration of intrapleural fibrinolytics in patients with septated MPE (8, 9) . This improvement could be due to an increase in fluid output of approximately 100 ml in the urokinase group, although this difference did not reach statistical significance. Although different fibrinolytics were used in these studies, there is no reason to hypothesize any difference in efficacy between fibrinolytics. Intrapleural urokinase was not associated with any adverse reactions, suggesting it is safe for use in patients with MPE.
In light of these results, is it appropriate to insert a chest tube and attempt pleurodesis in patients with a septated MPE that is unlikely to drain? Given the high mortality demonstrated in this study, we propose that outpatient treatments (such as therapeutic aspiration or indwelling pleural catheter [IPC] insertion) in conjunction with other palliative treatments for dyspnea (such as low-dose opiates) may be more appropriate for this patient group, with the aim being to provide dyspnea relief without a hospital admission. Alternatively, thoracoscopy may allow more effective drainage before pleurodesis in those able to tolerate this procedure.
This study has several limitations. The study did not reach the original recruitment target. However, this occurred in light of new data on the minimally important difference in VAS score used for measurement of dyspnea. On the basis of the data published during recruitment for this study, TIME3 would be adequately powered to exclude a clinically meaningful change in dyspnea after intrapleural urokinase. Completion of screening logs was variable between centers despite guidelines, with some sites including all patients with a chest tube for MPE and others including only patients fulfilling the eligibility criteria.
The TIME3 study results suggest important potential future areas of research. IPCs are increasingly used in the treatment of patients with MPE on the basis of randomized trials demonstrating improvement in dyspnea and reduced hospital stay (18) . Recognized IPC complications include blockage and development of septations, which are increasingly treated with intrapleural fibrinolytics. A retrospective case series suggested improvement in pleural fluid drainage and radiographic appearance using intrapleural fibrinolysis (19) , but this study demonstrates that these are not reliable surrogates for the key clinical outcomes of dyspnea relief and pleurodesis success. This suggests that prospective controlled trials are now required to assess the potential clinical benefits and harms of such treatment in IPC patients.
In summary, intrapleural urokinase does not improve dyspnea or pleurodesis success compared with placebo in patients with nondraining MPE treated with a chest tube and should not routinely be used as an ORIGINAL ARTICLE adjunct to pleurodesis. This subgroup of patients has high mortality and significant residual dyspnea despite chest tube insertion, and alternative palliative measures should be considered for the relief of dyspnea. The potential benefits of this treatment in improving hospital stay, chest radiographic appearance, and mortality should be further investigated. n Author disclosures are available with the text of this article at www.atsjournals.org.
